ArticleBMC gastroenterology2026
Multicentre validation and comparison of 23 noninvasive diagnostic models for liver fibrosis in treatment-naïve Chinese patients with autoimmune hepatitis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLimitations of liver biopsy have driven the development of noninvasive liver fibrosis assessment models. Most noninvasive liver fibrosis models have been developed in hepatitis B or C cohorts but not in autoimmune hepatitis (AIH) cohorts. This study aimed to evaluate and compare the predictive performance of 23 existing noninvasive models for fibrosis staging in untreated Chinese patients with AIH.
methodsA multicentre retrospective study was conducted on 258 untreated patients with autoimmune hepatitis who underwent liver biopsy. Histological fibrosis stage was evaluated using the Ishak scoring system. The diagnostic accuracy of the 23 noninvasive models was assessed by the area under the receiver operating characteristic curve (AUROC), including the aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), age-platelet index (APind), aspartate aminotransferase (AST) to platelet ratio index (APRI), cirrhosis discriminant score (CDS), Doha score, fibrosis-4 index (FIB-4), fibrosis quotient (FibroQ), globulin/platelet model (GP), gamma-glutamyl transpeptidase to platelet ratio (GPR), Göteburg University cirrhosis index (GUCI), Hb-F, King's score, Lok index, Pohl score, S index, fibrosis-5 index (FIB-5), red cell distribution width-to-platelet ratio (RPR), Forns index, Fibro-alpha, globulin-albumin ratio (GAR), and age platelet count index.
resultsThe median age of the 258 patients was 53 (45-58) years, in which 236 (91.47%) patients were females. Significant fibrosis and cirrhosis were present in 79.84% and 9.30% of patients, respectively. For predicting significant fibrosis, the AUROCs of APind, GP, FIB-4, HB-F, the Lok index, the RPR, the Fibro-alpha index, and the age platelet count index exceeded 0.700. All the models had AUROCs < 0.700 for advanced fibrosis, whereas the Doha score, FI, GP, RPR, and Fibro-alpha achieved AUROCs > 0.700 for diagnosing cirrhosis. In terms of the grading system, the GP model outperformed other noninvasive models for assessing liver fibrosis in this cohort.
conclusionsIn Chinese treatment-naïve AIH patients, the use of the GP model has moderate diagnostic value for liver fibrosis and cirrhosis. Most existing noninvasive models demonstrate suboptimal accuracy, especially for advanced fibrosis. Further development and validation of noninvasive AIH-specific models are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.